"We believe that SF3B1 mutations have the potential to become key components of standard diagnostic panels with clinical utility in the management of patients suffering from CLL," states Antonius Schuh, TrovaGene's Chief Executive Officer. "We plan to offer laboratory-developed tests to detect SF3B1 mutations and to identify opportunities for the development of in-vitro diagnostic products incorporating our proprietary markers."
About TrovaGene, Inc.
Headquartered in San Diego, California, TrovaGene has focused on the development of its patented technology for the detection of transrenal DNA and RNA, short nucleic acid fragments, originating from normal and diseased cell death that cross the kidney barrier and can be detected in urine.
TrovaGene has a dominant patent position as relates to transrenal molecular testing. TrovaGene has U.S. and European patent applications and issued patents that cover testing for HPV and other infectious diseases, cancer, transplantation, prenatal and genetic testing. In addition, it owns worldwide rights to nucleophosmin-1 (NPM1), an informative biomarker for acute myeloid leukemia (AML). TrovaGene has filed a Form 10 with the SEC. More complete current information about TrovaGene is contained in the filing.
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on TrovaGene's current expectations and a
|SOURCE Trovagene, Inc.|
Copyright©2010 PR Newswire.
All rights reserved